The UK MHRA allows clinical trials of amycin "pre-drug" AVA6000 to treat solid tumors

Pharmaceutical company Avcta recently announced that it has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin a Phase I clinical trial of AVA6000, a "pre-drug" of amycin.
study will assess the effectiveness of AVA6000 in treating solid tumors.
AVA6000 is a pre-drug form of the chemotherapy atomycin that has been modified using the company's PreSION chemical method.
AVA6000 is cyclic inactivated until it enters the tumor micro-environment and is then activated by fibroblast activation protein (FAP).
FAP enzyme is common in most solid tumors, but not in healthy tissues such as the heart.
MHRA has approved Phase I clinical studies in the UK for patients with locally advanced or metastatic solid tumors (known to be FAP-positive), including pancreatic, colorectal, breast, ovarian, bladder, non-small cell lung cancer, head and neck squamous cell carcinoma and soft tissue sarcoma.
Avacta's chief development officer Neil Bell said: "Despite coVID-19 restrictions, Avacta plans to give our first patients in the UK by mid-2021."